Status:
COMPLETED
Bulking Agents for the Treatment of Stress Urinary Incontinence in Females
Lead Sponsor:
Contura
Collaborating Sponsors:
Regulatory and Clinical Research Institute Inc
Conditions:
Stress Urinary Incontinence
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The primary purpose of this study is to demonstrate the safety and effectiveness of Bulkamid® in the treatment of stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD) in adult...
Detailed Description
The study is a single-masked, randomized, comparative multi-center, 2-arm parallel study intended to demonstrate the safety and effectiveness of Bulkamid® vs. Contigen® for the treatment of stress uri...
Eligibility Criteria
Inclusion
- Be female 18 or more years of age.
- Females of childbearing potential or \<2 years post-menopausal must be using 2 forms of contraception.
- Suffer from SUI for at least 6 months.
- Have failed 2 previous non-invasive therapies for 3 months each.
- Have at least 3 incontinence episodes measured over 3 days.
- Have a baseline 24h pad test weight greater than or equal to 5 gm.
- Have VLPP ≤ 100 cm H2O.
- Have maximum cystometric capacity equal or higher than (≥) 250 mL.
- Have PVR urine ≤ 100 mL.
- Have a life expectancy of more than 2 years.
Exclusion
- Has urethral hypermobility \>30 deg.
- Has predominant urge incontinence.
- Has detrusor overactivity.
- Regularly or intermittently users of urethral catheter.
- Has had previous radiation treatment in the pelvic floor.
- Has had previous urethral surgery (i.e. fistula, diverticula)or urethral bulking. Failed sling or colposuspension procedure for at least 6 months may be included.
- Suffers from known polyuria.
- Has had three (3) or more culture-proven bacterial UTIs in the last 12 months.
- Has a current infection (urethritis, cystitis or vaginitis).
- Has unevaluated hematuria.
- Has a Prolapse Stage greater than II.
- Has a BMI\>35 kg/m2.
- Is taking pharmacological treatment for stress urinary incontinence, 4 weeks prior to screening.
- Is allergic to bovine collagen.
- Is known to suffer from severe allergies or anaphylaxis.
- Suffers from autoimmune diseases (e.e. connective tissue diseases) that could confound the treatment.
- Is currently taking or has taken systemic corticosteroids within the past 3 months.
- Currently has cancer or has a history of any cancer within the past 5 years (skin cancer with no evidence of skin malignancy, for at least 2 years, can be included).
- Currently suffering from unstable cardiovascular disease, cancer or uncontrolled diabetes.
- Has active herpes genitalis.
- Is currently participating in any other clinical trial or has participated in another clinical trial within 3 months of screening/baseline visit.
- Is pregnant, lactating or intending to become pregnant.
- Is not physically able to perform study procedure.
- Has a neurogenic bladder
- Had a vaginal delivery within 3 months prior to screening.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
345 Patients enrolled
Trial Details
Trial ID
NCT00629083
Start Date
April 1 2008
End Date
May 1 2013
Last Update
February 7 2020
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Incontinence Research Institute
Encinitas, California, United States, 92024
2
Tower Urology - Institute for Continence - Cedars-Sinai Medical Office
Los Angeles, California, United States, 90048
3
Sherif Aboseif, MD
Oxnard, California, United States, 93030
4
South California Permanente Medical Group
Pasadena, California, United States, 91101